Ab­b­Vie sues five gener­ic com­pa­nies over po­ten­tial Rin­voq com­peti­tors

Ab­b­Vie spent the last decade pro­tect­ing its top-sell­ing Hu­mi­ra (adal­i­mum­ab) fran­chise from biosim­i­lar com­pe­ti­tion, and now the Chica­go-based com­pa­ny is su­ing five gener­ic drug com­pa­nies over po­ten­tial com­peti­tors to one of its oth­er lead­ing rheuma­toid arthri­tis drugs, Rin­voq (upadac­i­tinib).

Just as Ab­b­Vie used a fortress of patents to pro­tect Hu­mi­ra, the com­pa­ny is cit­ing more than 30 patents for Rin­voq that it says have been in­fringed up­on by San­doz, In­tas, Sun Phar­ma­ceu­ti­cal, Au­robindo and Het­ero USA. All five com­pa­nies have filed their in­fring­ing ap­pli­ca­tions for Rin­voq gener­ics with the FDA, Ab­b­Vie al­leges.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER